{"commentary":{"count":20,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"podcast":7,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03740165\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03740165","nct_id":"NCT03740165","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03740165. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants receive carboplatin/paclitaxel via intravenous (IV) infusion for five 3-week cycles PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS olaparib 300 mg via oral tablet twice each day (BID), starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.","label":"Carboplatin + Paclitaxel + Pembrolizumab + Olaparib","type":"EXPERIMENTAL"},{"description":"Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles starting in Cycle 1 PLUS pembrolizumab 200 mg via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.","label":"Carboplatin + Paclitaxel + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive carboplatin/paclitaxel via IV infusion for five 3-week cycles PLUS placebo for pembrolizumab (normal saline or dextrose) via IV infusion on Day 1 of each 3-week cycle for up to 35 cycles PLUS placebo for olaparib via oral tablet BID, starting with Cycle 7. Participants who experience severe hypersensitivity reaction to paclitaxel or an AE requiring discontinuation of paclitaxel may receive docetaxel (75 mg/m\\^2 Q3W) plus carboplatin AUC 5 Q3W after Sponsor consultation. Participants may also receive bevacizumab via IV infusion on Day 1 of each 3-week cycle at the Investigator's discretion.","label":"Carboplatin + Paclitaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":["European Network of Gynaecological Oncological Trial Groups (ENGOT)","Gynecologic Oncology Group"],"completion_date":{"date":"2026-04-14","type":"ACTUAL"},"conditions":["Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Neoplasms"],"enrollment":{"count":1367,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Placebo for pembrolizumab","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Paclitaxel","type":"DRUG"},{"name":"Olaparib","type":"DRUG"},{"name":"Placebo for olaparib","type":"DRUG"},{"name":"Bevacizumab","type":"BIOLOGICAL"},{"name":"Docetaxel","type":"DRUG"}],"last_update":"2026-08-19","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2024-08-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)","timeFrame":"Up to approximately 67 months"},{"measure":"PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants","timeFrame":"Up to approximately 67 months"}],"references":[{"citation":"Vergote I, Cibula D, Powell M, Laenen A, Nieuwenhuysen EV, Topuz S, Gonzalez-Martin A, Fujiwara K, Safina S, Bagameri A, Oliver M, Lee JY, Salutari V, Korach J, Lu CH, Madry R, Vulsteke C, Colombo N, Sehouli J, Klat J, Ruiz EY, Gilbert L, Pautier P, Pardo B, Kridelka F, Wei J, Toker S, Yamada K, Coleman RL; ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2026 Sep 7:S1470-2045(26)00223-8. doi: 10.1016/S1470-2045(26)00223-8. Online ahead of print.","pmid":"42705254","type":"DERIVED"}],"start_date":{"date":"2018-12-18","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)","url":"https://clinicaltrials.gov/study/NCT03740165"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03740165"}